Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer

Kufukihara, Ryohei; Kikuchi, Eiji; Ogihara, Koichiro; Shigeta, Keisuke; Yanai, Yoshinori; Takamatsu, Kimiharu; Ide, Hiroki; Oyama, Masafumi; Asakura, Hirotaka; Mizuno, Ryuichi; Oya, Mototsugu

doi:10.1245/s10434-021-09750-0

Cited by 5 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Kufukihara et al. ( 24 ) revealed that the rate of bladder tumor recurrence was significantly lower in the ADT group than in the counterpart ( p = 0.027). However, McMartin et al.…”

Section: Resultsmentioning

confidence: 75%

“…The pooled analysis for RFS detected significant heterogeneity (I 2 = 90%, p < 0.001). Similarly, Kufukihara et al (24) revealed that the rate of bladder tumor recurrence was significantly lower in the ADT group than in the counterpart (p = 0.027). However, McMartin et al (26) failed to find a significant difference in RFS between patients undergoing therapy with 5-ARIs and controls.…”

Section: Effect Of Ast On Bladder Cancer Recurrence and Progressionmentioning

confidence: 80%

“…Owing to a paucity of HR data from PFS, we performed a descriptive analysis. PFS was investigated in 4 studies, and no differences between AST users and nonusers were found ( 21 , 24 , 31 , 37 ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis

Xiang

Hao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeThe purpose of this study was to summarize the existing evidence and develop a comprehensive systematic review of the impact of androgen suppression therapy (AST) on the incidence or clinical outcomes of bladder cancer.MethodsWe systematically searched the PubMed and Embase databases from inception to June 20, 2021 to identify all observational studies examining the incidence or clinical outcomes of bladder cancer in patients who received AST. AST is defined as the use of 5-alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT).ResultsA total of 18 observational studies were included. Our results showed that AST was not significantly associated with a reduced risk of BCa incidence (OR: 0.92, 95% CI: 0.68–1.24) compared with the lack of AST. The subgroup analysis revealed that finasteride use was significantly associated with a reduction in the risk of BCa incidence (OR: 0.75, 95% CI: 0.64–0.88). Recurrence-free survival (RFS) was improved among AST users compared with nonusers (HR: 0.68, 95% CI: 0.48–0.95), while no significant difference between AST users versus nonusers was identified for cancer-specific survival (CSS), overall survival (OS) or progression-free survival (PFS).ConclusionCurrent evidence indicates that therapy with finasteride may represent a potential strategy aimed at reducing BCa incidence. Moreover, AST has a beneficial effect on the recurrence of bladder cancer. Further well-designed randomized trials or cohort studies with better characterized study populations are needed to validate our preliminary findings.Systematic Review RegistrationInternational Prospective Register of Systematic Reviews database [https://www.crd.york.ac.uk/PROSPERO/], identifier CRD42021261685.

show abstract

Section: Resultsmentioning

confidence: 75%

Section: Effect Of Ast On Bladder Cancer Recurrence and Progressionmentioning

confidence: 80%

See 1 more Smart Citation

Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis

Xiang

Hao

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…According to our results, we found that previous non-urothelial cancers could significantly increase the risk of UCs recurrence, especially the IVR. Ryohei et al also reported that non-urothelial malignant history could increase the risk of recurrence for patients with non-muscle invasive bladder cancer (NMIBC) [ 10 ]. We think the main reason for this situation is the field change cancerization effect [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma

et al. 2023

View full text Add to dashboard Cite

Background The evidence of prognostic factors and individualized surveillance strategies for upper tract urothelial carcinoma are still weak. Objectives To evaluate whether the history of previous malignancy (HPM) affects the oncological outcomes of upper tract urothelial carcinoma (UTUC). Methods The CROES-UTUC registry is an international, observational, multicenter cohort study on patients diagnosed with UTUC. Patient and disease characteristics from 2380 patients with UTUC were collected. The primary outcome of this study was recurrence-free survival. Kaplan-Meier and multivariate Cox regression analyses were performed by stratifying patients according to their HPM. Results A total of 996 patients were included in this study. With a median recurrence-free survival time of 7.2 months and a median follow-up time of 9.2 months, 19.5% of patients had disease recurrence. The recurrence-free survival rate in the HPM group was 75.7%, which was significantly lower than non-HPM group (82.7%, P = 0.012). Kaplan-Meier analyses also showed that HPM could increase the risk of upper tract recurrence (P = 0.048). Furthermore, patients with a history of non-urothelial cancers had a higher risk of intravesical recurrence (P = 0.003), and patients with a history of urothelial cancers had a higher risk of upper tract recurrence (P = 0.015). Upon multivariate Cox regression analysis, the history of non-urothelial cancer was a risk factor for intravesical recurrence (P = 0.004), and the history of urothelial cancer was a risk factor for upper tract recurrence (P = 0.006). Conclusion Both previous non-urothelial and urothelial malignancy could increase the risk of tumor recurrence. But different cancer types may increase different sites’ risk of tumor recurrence for patients with UTUC. According to present study, more personalized follow-up plans and active treatment strategies should be considered for UTUC patients.

show abstract

“…1 Although non-muscle invasive bladder cancer (NMIBC) accounts for approximately 75% of all BLCA, 2 the major concern is its high rates of recurrence, progression and even metastasis after appropriate primary curative treatment or sequential intravesical therapy. 3 Subsequently, cisplatin-based combination chemotherapy is widely used as the standard first-line systemic treatment for patients who present with muscle-invasive bladder cancer (MIBC) or metastatic disease. 4 Nevertheless, even with this kind of therapy, the median overall survival is still poor, which is estimated to be about 12-14 months.…”

Section: Introductionmentioning

confidence: 99%

STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer

Sun¹,

Wei²,

You³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background: Stanniocalcin-1 (STC1) is a well-studied oncogene that promotes different types of cancer progression. However, the expression status of STC1, the values of STC1 on prognosis, and its immune characteristic in bladder cancer (BLCA) have not been well examined. Methods: The expression of STC1 and its clinicopathological as well as immune characteristics in BLCA samples were firstly identified in The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Immunohistochemistry (IHC) performed on the tissue microarray (TMA) slide was further used to validate the expression of STC1 and its relationship with immune features in 16 non-muscle invasive bladder cancer (NMIBC) samples and 42 muscle invasive bladder cancer (MIBC) samples. Results: The expression of STC1 was upregulated in higher stage BLCA. High STC1 expression also predicted poor prognosis in BLCA. Subsequently, the TMA validated the expression and prognostic value of STC1 in BLCA. Bioinformatics analysis demonstrated that STC1 and common immune checkpoints as well as immune markers of various immune cells were positively correlated in TCGA. In addition, IHC data from the TMA further validated that tumor cells with higher STC1 level tended to express higher PDL1 as well as increased infiltration of CD3+ T cells. Conclusion:To our knowledge, this is the first comprehensive study that investigates the clinical and immune characteristics of STC1 in BLCA. It may provide new insight into the function of STC1 in regulating tumor immune microenvironment. Further studies are warranted to uncover the potential mechanisms that mediate STC1 expression and tumor immunity in BLCA.

show abstract

Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer

Cited by 5 publications

References 25 publications

Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis

Impact of Androgen Suppression Therapy on the Risk and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis

Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma

STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer

Contact Info

Product

Resources

About